SNSS - Sunesis Pharmaceuticals, Inc.
| Previous Close | 0.3052 |
| Open | 0.3100 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.3052 - 0.3299 |
| 52 Week Range | 0.2000 - 1.7700 |
| Volume | 1227730 |
| Avg. Volume | 1,647,452 |
| Market Cap | 35M |
| Beta (5Y Monthly) | 2.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
- Benzinga
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
- Benzinga
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
- GlobeNewswire
Sunesis Pharmaceuticals Announces Data from Ongoing Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced data from the Company’s Phase 1b/2 clinical trial of its non-covalent.
- Thomson Reuters StreetEvents
Edited Transcript of SNSS earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 Sunesis Pharmaceuticals Inc Earnings Call
- GlobeNewswire
Sunesis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Highlights
Phase 1b/2 Trial of Vecabrutinib in 400 mg Cohort; Clinical Update at Upcoming ASH Annual Meeting Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN.
- GlobeNewswire
Sunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President,.
- GlobeNewswire
Sunesis Pharmaceuticals Announces Presentation at 61st American Society of Hematology Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 61st American Society of Hematology.
- GlobeNewswire
Sunesis Pharmaceuticals to Host Conference Call on November 12th to Discuss Third Quarter 2019 Financial Results and Recent Highlights
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Tuesday, November 12th, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2019.
- American City Business Journals
These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
- GlobeNewswire
Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 2019 AACR-NCI-EORTC International.
- GlobeNewswire
Sunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto brings over 20 years of oncology drug development experience to the Board. “Dr. Onetto’s broad experience in oncology and hematology will be invaluable to Sunesis as we develop our kinase inhibitor pipeline, including our lead asset, the non-covalent BTK inhibitor vecabrutinib,” said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. “Dr. Onetto brings to Sunesis a distinguished career with a wealth of experience operationally and strategically in developing and bringing novel and innovative oncology drugs to patients.
- Simply Wall St.
The Sunesis Pharmaceuticals (NASDAQ:SNSS) Share Price Is Down 98% So Some Shareholders Are Very Salty
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shareholders should be happy to see the share price up 24% in the last...
- Zacks
Sunesis Pharmaceuticals, Inc. (SNSS) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. (SNSS).
- GlobeNewswire
Sunesis Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President of Finance and Corporate Development, will present at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at 10:50 AM Eastern Time in Boston. Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer.
- Thomson Reuters StreetEvents
Edited Transcript of SNSS earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 Sunesis Pharmaceuticals Inc Earnings Call
- Zacks
Sunesis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Sunesis Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
- GlobeNewswire
Sunesis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2019. Loss from.
- GlobeNewswire
Sunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2019 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., July 31, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, August 7th, 2019 at.
- Simply Wall St.
How Many Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Shares Do Institutions Own?
A look at the shareholders of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) can tell us which group is most powerful...
- Benzinga
The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ...
- GlobeNewswire
Sunesis Announces Pricing of $25 Million Offering of Securities
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible Preferred Stock (“Series F Stock”). The public offering price of each share of common stock is $0.60 and the public offering price of each share of Series F Stock, convertible into 1,000 shares of common stock, is $600. Sunesis expects to receive combined gross proceeds of approximately $25 million from these offerings, before deducting the underwriting discounts and other estimated offering expenses. Sunesis has granted the underwriters a 30 day option to purchase up to an additional 5,000,050 shares of common stock to cover over-allotments, if any.
- GlobeNewswire
Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offerings to fund ongoing development of vecabrutinib, ongoing research and development, and general corporate purposes.
- GlobeNewswire
Sunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the promotion of Judy Fox, Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific Officer, Executive Vice President, Research & Development and the promotion of Parvinder (Par) S. Hyare from Vice President, Global Oncology Operations to Senior Vice President, Commercial. Dr. Fox received her Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology, and an A.B. in Chemistry from Bryn Mawr College.
- Zacks
Options Traders Expect Huge Moves in Sunesis (SNSS) Stock
Investors need to pay close attention to Sunesis (SNSS) stock based on the movements in the options market lately.
- GlobeNewswire
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results are being presented today, June 15, from 5:30-7:00 p.m. CET in a poster session titled “Chronic lymphocytic leukemia and related disorders – Clinical” at the 24th Congress of the European Hematology Association (EHA) in Amsterdam. The poster, titled “Preliminary Results of a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor (BTKi) Vecabrutinib in B-Cell Malignancies,” Abstract No. PS1148, is available at www.sunesis.com.
